Highlighted Article – Targeting Malassezia species for Novel Synthetic and Natural Antidandruff Agents – Current Medicinal Chemistry

cmc-Articles_24-42-Claudiu T. Supuran

http://www.eurekaselect.com/151310/article

Upcoming Thematic Issue – Drug Induced Nephrotoxity and Drug Metabolism in Renal Failure – Current Drug Metabolism

CDM- THEMATIC FLYER -Jiaguo Huang

http://benthamscience.com/journals/current-drug-metabolism/special-issues/

New Issue :: Current Medicinal Chemistry 24, Issue 7

Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews and guest edited thematic issues written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.

cmc

Articles from the journal Current Medicinal Chemistry 24, Issue 7:

For details on the articles, please visit this link :: goo.gl/k2qdt6

 

 

 

 

Most Accessed Article – Neoadjuvant Therapy for HER2-positive Breast Cancer – Reviews on Recent Clinical Trials

Journal: Reviews on Recent Clinical Trials

Author(s): Rachel Wuerstlein, Nadia Harbeck.

Graphical Abstract:

 

Abstract:

In HER2-positive early breast cancer, neoadjuvant treatment with a combination of sequential chemotherapy and HER2-targeted therapy is currently the standard of care. This is followed by breast surgery, radiotherapy (if indicated), completion of 12 months of HER2-directed therapy, and – depending on the tumor biology – endocrine adjuvant therapy, and ultimately follow up.

10-year survival rates in the HER2-positive subgroup of breast cancer do reach now more than 75% with the introduction of first adjvuant and later neoadjuvant HER2-targeted therapies over the last 15 years. The neoadjvuant setting helps to downstage locally advanced tumors, to provide early information of tumor response, to assess the efficacy of new therapies in vivo, to reduce treatment duration, and to introduce new targeted therapies into the clinical routine. It also allows enrolling fewer patients into clinical trials in order to reach adequate effects in clinical outcome.

The neoadjuvant approach and our interest in this setting are based on pCR (pathological complete response) and its translation into better long-term outcome. In recent trials, we have reached more than 60% pCR with a subsequent improvement of DFS and hopefully OS. Therefore, chemotherapy schedules and new HER2-targeted agents such as lapatinib, pertuzumab, and T-DM1 have been introduced into the neoadjuvant setting. To balance over- and undertreatment, current trials include personalized concepts and assess new biomarkers and tumorbiological factors. We have learned for example to differentiate between HR (hormone receptor)-positive and -negative tumors in the HER2-positive population. Depending on pCR or non-pCR after neoadjuvant treatment, the adjuvant therapy may be adjusted. This concept of post-neo-adjuvant trials is now entering the field of strategies in the neoadjuvant setting for HER2-positive non-metastatic primary breast cancer.
The 2017 standard of care in the neoadjuvant setting according to national and international guidelines combines a taxane-containing chemotherapy with a dual blockade of trastuzumab and pertuzumab.
This review will point out current trials and their strategies to continue improving outcome and reduce morbidity as well as mortality in HER2-positive early breast cancer.

Highlighted Article – Sarcopenia: An Overview on Current Definitions, Diagnosis and Treatment – Current Protein & Peptide Science

cpps-Articles_18-12-Francesco Landi.jpg

http://www.eurekaselect.com/152966/article

Testimonial by Jaya Kumar!

jaya kumar

Contributed Article: Alcohol Addiction- Metabotropic Glutamate Receptor Subtype 5 and its Ligands: How They All Come Together

New Issue :: Current Proteomics 14, Issue 2

Research in the emerging field of proteomics is growing at an extremely rapid rate. The principal aim of Current Proteomics is to publish well-timed review articles in this fast-expanding area on topics relevant and significant to the development of proteomics. Current Proteomics is an essential journal for everyone involved in proteomics and related fields in both academia and industry.

Current Proteomics publishes review articles in all aspects of the fast-expanding field of proteomics. All areas of proteomics are covered together with the methodology, softwares, databases, technological advances and applications of proteomics, including functional proteomics.

cp

Articles from the journal Current Proteomics 14, Issue 2:

For details on the articles, please visit this link :: http://bit.ly/2vB39dJ

 

Upcoming Thematic Issue – The importance of food perception in consumer choices and nutrition – Recent Patents on Food, Nutrition & Agriculture

RPFNA- THEMATIC FLYER -Elsa Lamy - PhD

http://benthamscience.com/journals/recent-patents-on-food-nutrition-and-agriculture/special-issues/

Article by Disease – Inhibition of the VEGF/VEGFR Pathway Improves Survival in Advanced Kidney Cancer – Current Drug Targets

ARTICLE BY DISEASE ON “KIDNEY CANCER

Abstract:

Despite the improvement in progression-free survival and response rates, none of the five anti- VEGF/VEGFR agents used for treatment of metastatic renal cell carcinoma (mRCC) reported a significant increase in patients’ survival. This analysis aims to investigate their effect on overall survival (OS), performing a meta-analysis of the available studies. MEDLINE/PubMed and the Cochrane Library were searched for randomised phase III trials that compared anti-VEGF/VEGFR agents with controls as upfront treatment for mRCC. The search was restricted to phase III trials, and data extraction was conducted according to the PRISMA statement. Five randomised phase III trials were included for a total of 3,469 patients; among these, 1,801 received anti-VEGF/VEGFR agents and 1,668 were treated with a placebo or interferon-α. In the overall population, the reduction in the risk of death was 13% (HR: 0.87; 95%CI, 0.80 – 0.95; p=0.002). When patients were divided based on use of VEGFR agents or an anti-VEGF monoclonal antibody, the reduction in the risk of death was 13% and 12%, respectively. If only treatmentnaïve patients are considered, we can confirm a significant reduction of 12% (HR=0.88; 95%CI, 0.79 – 0.97; p=0.010) in the risk of death. Our analysis reports a positive improvement of OS with the inhibition of the VEGF/VEGFR pathway in mRCC.

Read more: http://www.eurekaselect.com/node/126194/article

Testimonial by Jagdish Rai!

Jagdish Rai

Contributed Article: Mini heme-proteins: Designability of structure and diversity of functions